Find Inosine Pranobex manufacturers, exporters & distributors on PharmaCompass

Inosine Pranobex

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

4 API Suppliers, 4 Listed Suppliers

DEVELOPMENTS

2 Drug(s) in Development

2 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports

INTERMEDIATES

1 Suppliers

1 Suppliers

DOSSIERs // Finished Dosage Formulations

11 Dossiers, 8 Europe, 1 Canada, 2 Listed Dossiers

GLOBAL SALES INFORMATION

3 Finished Drug Prices

3 Finished Drug Prices

MARKET PLACE

2 APIs, 2 DOSSIERS // FDF

DIGITAL CONTENT

1 News

1 News

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

EU WC

Listed Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Isoprinosine, 36703-88-5, Inosiplex, Delimmun, Methisoprinol, Imunovir

Molecular Formula

C₅₂H₇₈N₁₀O₁₇

Molecular Weight

1115.2 g/mol

InChI Key

YLDCUKJMEKGGFI-QCSRICIXSA-N

FDA UNII

W1SO0V223F

An alkylamino-alcohol complex of inosine used in the treatment of a variety of viral infections. Unlike other antiviral agents, it acts by modifying or stimulating cell-mediated immune processes rather than acting on the virus directly.

1 2D Structure

Inosine Pranobex

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-acetamidobenzoic acid;9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one;1-(dimethylamino)propan-2-ol

2.1.2 InChI

InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;;;/m1....../s1

2.1.3 InChI Key

YLDCUKJMEKGGFI-QCSRICIXSA-N

2.1.4 Canonical SMILES

CC(CN(C)C)O.CC(CN(C)C)O.CC(CN(C)C)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O

2.1.5 Isomeric SMILES

CC(CN(C)C)O.CC(CN(C)C)O.CC(CN(C)C)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O

2.2 Other Identifiers

2.2.1 UNII

W1SO0V223F

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Imunovir

2. Inosiplex

3. Isoprinosin

4. Isoprinosine

5. Methisoprinol

6. Methysoprinol

7. Metisoprinol

8. Npt 10381

9. Npt-10381

10. Npt10381

11. Pranobex, Inosine

2.3.2 Depositor-Supplied Synonyms

1. Isoprinosine

2. 36703-88-5

3. Inosiplex

4. Delimmun

5. Methisoprinol

6. Imunovir

7. Isoviral

8. Viruxan

9. Isoprinosin

10. Isoprinosina

11. Aviral

12. Inosine Acedobene Dimepranol

13. Imunoviral

14. Modimmunal

15. Immunovir

16. Pranosina

17. Pranosine

18. Np 113

19. Npt-10381

20. W1so0v223f

21. Np-113

22. Inosine Pranobex (jan)

23. Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)

24. Inosine Pranobex [jan]

25. 4-acetamidobenzoic Acid,9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3h-purin-6(9h)-one,1-(dimethylamino)propan-2-ol (3:1:3)

26. 4-acetamidobenzoic Acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol

27. Inosine Pranobex [ban:jan]

28. Einecs 253-162-1

29. Ntp 10381

30. Unii-w1so0v223f

31. Groprinosin

32. Isoprinosine (tn)

33. Inosine, Compd. With 1-(dimethylamino)-2-propanol 4-(acetylamino)benzoate (salt) (1:3)

34. Inosine, Compound With (2-hydroxypropyl)dimethylammonium P-acetamidobenzoate (1:3)

35. Inosine Pranobex [mi]

36. Chembl3833327

37. Inosine Pranobex [mart.]

38. Inosine Pranobex [who-dd]

39. Dtxsid401021342

40. Iad

41. Mfcd05662374

42. S5016

43. Akos025312516

44. Akos030228417

45. Ccg-270642

46. As-12319

47. Hy-107801

48. Cs-0030676

49. I1037

50. C74892

51. D01995

52. 703i885

53. A874300

54. Q3130053

55. P-acetamidobenzoic Salt Of N,n-dimethylamino-2-propanol & Inosine (3:1)

56. Inosine & 1-(dimethylamino)-2-propanol & 4-(acetylamino)benzoate (salt) (1:3:3)

57. 4-acetamidobenzoic Acid; 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purin-6-one; 1-(dimethylamino)propan-2-ol

58. 4-acetamidobenzoic Acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one;1-(dimethylamino)propan-2-ol

2.4 Create Date

2019-01-15

3 Chemical and Physical Properties

Molecular Formula	C₅₂H₇₈N₁₀O₁₇
Molecular Weight	1115.2 g/mol
Hydrogen Bond Donor Count	13
Hydrogen Bond Acceptor Count	22
Rotatable Bond Count	14
Exact Mass	1114.55464106 g/mol
Monoisotopic Mass	1114.55464106 g/mol
Topological Polar Surface Area	399 Å²
Heavy Atom Count	79
Formal Charge	0
Complexity	658
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	3
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	7

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Adjuvants, Immunologic

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)

Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)

4.2 ATC Code

J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AX - Other antivirals

J05AX05 - Inosine pranobex